Letter: Dry blood spots for anti-TNF treatment monitoring in IBD

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 10, 2013, Pages 1024-1025

  Vande Casteele, N ^a   Brecx, S ^a   Declerck, P ^a   Ferrante, M ^b   Rutgeerts, P ^b   Vermeire, S ^b   Gils, A ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACCURACY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENTERITIS; HEMATOCRIT; HUMAN; LETTER; LIMIT OF QUANTITATION; PRIORITY JOURNAL; TREATMENT FAILURE; VALIDATION PROCESS;

HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE;

EID: 84876458649     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12283     Document Type: Letter

References (5)

1. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP,. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-86.
2. Vande Casteele N, Compernolle G, Ballet V, et al,. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohn's Colitis 2012; 6: S6.
3. Timmerman P, White S, Globig S, Ludtke S, Brunet L, Smeraglia J,. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis 2011; 3: 1567-75.
4. Edelbroek PM, van der Heijden J, Stolk LM,. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009; 31: 327-36.
5. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al,. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.